Podcasts about Sarepta

Meditación del Evangelio según San Lucas 4, 16-30 por el biblista P. Norberto Padilla, misionero claretiano.Lunes 1/sept/2025, Me ha enviado para dar la Buena Noticia a los pobres... Ningún profeta es bien mirado en su tierra.Canción: Espíritu (2020), de Jesús Cabello----------Lectura del santo evangelio según san Lucas 4, 16-30En aquel tiempo, fue Jesús a Nazaret, donde se había criado. Entró en la sinagoga, como era su costumbre los sábados, y se puso en pie para hacer la lectura. Le entregaron el libro del profeta Isaías y, desarrollándolo, encontró el pasaje donde estaba escrito: "El Espíritu del Señor está sobre mí, porque él me ha ungido. Me ha enviado para dar la buena noticia a los pobres, para anunciar a los cautivos la libertad, y a los ciegos la vista; para dar libertad a los oprimidos, para anunciar el año de gracia del Señor." Y, enrollando el libro, lo devolvió al que le ayudaba y se sentó. Toda la sinagoga tenía los ojos fijos en él. Y él se puso a decirles: "Hoy se cumple esta Escritura que acaban de oír." Y todos le expresaban su aprobación y se admiraban de las palabras de gracia que salían de sus labios. Y decían: "¿No es este el hijo de José?" Y Jesús les dijo: "Sin duda me recitarán aquel refrán: 'Médico, cúrate a ti mismo, haz también aquí en tu tierra, lo que hemos oido que haz hecho en Cafarnaún'". Y añadió: "Les aseguro que ningún profeta es bien mirado en su tierra. Les garantizo que en Israel habían muchas viudas en tiempos de Elías, cuando estuvo cerrado el cielo tres años y seis meses, y hubo una gran hambre en todo el país. Sin embargo a ninguna de ellas fue enviado Elías, mas que a una viuda de Sarepta en el territorio de Sidón. Y muchos leprosos había en Israel en tiempos del profeta Eliseo; sin embargo, ninguno de ellos fue curado, mas que Naamán, el Sirio". Al oír esto, todos en la sinagoga se pusieron furiosos y, levantándose, lo empujaron fuera del pueblo, hasta un barranco del monte donde se alzaba su pueblo, con intención de despeñarlo. Pero Jesús se abrió paso entre ellos y se alejaba.Palabra del Señor... Gloria a ti, Señor Jesús#SoyClaretiano #Evangelio #MisionerosClaretianos #CMFAntillasIntro: Lámpara Es Tu Palabra, de Ain Karem

+ Evangelio de nuestro Señor Jesucristo según san Lucas 4, 16-30      Jesús fue a Nazaret, donde se había criado; el sábado entró como de costumbre en la sinagoga y se levantó para hacer la lectura. Le presentaron el libro del profeta Isaías y, abriéndolo, encontró el pasaje donde estaba escrito:        "El Espíritu del Señor está sobre mí,        porque me ha consagrado por la unción.        Él me envió a llevar la Buena Noticia los pobres,        a anunciar la liberación a los cautivos        y la vista a los ciegos,        a dar la libertad a los oprimidos        y proclamar un año de gracia del Señor.      Jesús cerró el Libro, lo devolvió al ayudante y se sentó. Todos en la sinagoga tenían los ojos fijos en él. Entonces comenzó a decirles: «Hoy se ha cumplido este pasaje de la Escritura que acaban de oír».       Todos daban testimonio a favor de él y estaban llenos de admiración por las palabras de gracia que salían de su boca. Y decían: «¿No es este el hijo de José?».      Pero Él les respondió: «Sin duda ustedes me citarán el refrán: "Médico, cúrate a ti mismo". Realiza también aquí, en tu patria, todo lo que hemos oído que sucedió en Cafarnaúm».      Después agregó: «Les aseguro que ningún profeta es bien recibido en su tierra. Yo les aseguro que había muchas viudas en Israel en el tiempo de Elías, cuando durante tres años y seis meses no hubo lluvia del cielo y el hambre azotó a todo el país. Sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda de Sarepta, en el país de Sidón. También había muchos leprosos en Israel, en el tiempo del profeta Eliseo, pero ninguno de ellos fue curado, sino Naamán, el sirio».      Al oír estas palabras, todos los que estaban en la sinagoga se enfurecieron y, levantándose, lo empujaron fuera de la ciudad, hasta un lugar escarpado de la colina sobre la que se levantaba la ciudad, con intención de despeñarlo. Pero Jesús, pasando en medio de ellos, continuó su camino.Palabra del Señor.

Lc 4,16-30.Jesús fue a Nazaret, donde se había criado; el sábado entró como de costumbre en la sinagoga y se levantó para hacer la lectura.Le presentaron el libro del profeta Isaías y, abriéndolo, encontró el pasaje donde estaba escrito:El Espíritu del Señor está sobre mí, porque me ha consagrado por la unción. El me envió a llevar la Buena Noticia a los pobres, a anunciar la liberación a los cautivos y la vista a los ciegos, a dar la libertad a los oprimidosy proclamar un año de gracia del Señor.Jesús cerró el Libro, lo devolvió al ayudante y se sentó. Todos en la sinagoga tenían los ojos fijos en él.Entonces comenzó a decirles: "Hoy se ha cumplido este pasaje de la Escritura que acaban de oír".Todos daban testimonio a favor de él y estaban llenos de admiración por las palabras de gracia que salían de su boca. Y decían: "¿No es este el hijo de José?".Pero él les respondió: "Sin duda ustedes me citarán el refrán: 'Médico, cúrate a ti mismo'. Realiza también aquí, en tu patria, todo lo que hemos oído que sucedió en Cafarnaún".Después agregó: "Les aseguro que ningún profeta es bien recibido en su tierra.Yo les aseguro que había muchas viudas en Israel en el tiempo de Elías, cuando durante tres años y seis meses no hubo lluvia del cielo y el hambre azotó a todo el país.Sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda de Sarepta, en el país de Sidón.También había muchos leprosos en Israel, en el tiempo del profeta Eliseo, pero ninguno de ellos fue curado, sino Naamán, el sirio".Al oír estas palabras, todos los que estaban en la sinagoga se enfurecierony, levantándose, lo empujaron fuera de la ciudad, hasta un lugar escarpado de la colina sobre la que se levantaba la ciudad, con intención de despeñarlo.Pero Jesús, pasando en medio de ellos, continuó su camino.

San Lucas 4, 16 – 30Jesús fue a Nazaret, donde se había criado; el sábado entró como de costumbre en la sinagoga y se levantó para hacer la lectura. Le presentaron el libro del profeta Isaías y, abriéndolo, encontró el pasaje donde estaba escrito: El Espíritu del Señor está sobre mí, porque me ha consagrado por la unción. Él me envió a llevar la Buena Noticia a los pobres, a anunciar la liberación a los cautivos y la vista a los ciegos, a dar la libertad a los oprimidos y proclamar un año de gracia del Señor. Jesús cerró el Libro, lo devolvió al ayudante y se sentó. Todos en la sinagoga tenían los ojos fijos en él. Entonces comenzó a decirles: "Hoy se ha cumplido este pasaje de la Escritura que acaban de oír". Todos daban testimonio a favor de él y estaban llenos de admiración por las palabras de gracia que salían de su boca. Y decían: "¿No es este el hijo de José?". Pero él les respondió: "Sin duda ustedes me citarán el refrán: 'Médico, cúrate a ti mismo'. Realiza también aquí, en tu patria, todo lo que hemos oído que sucedió en Cafarnaún". Después agregó: "Les aseguro que ningún profeta es bien recibido en su tierra. Yo les aseguro que había muchas viudas en Israel en el tiempo de Elías, cuando durante tres años y seis meses no hubo lluvia del cielo y el hambre azotó a todo el país. Sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda de Sarepta, en el país de Sidón. También había muchos leprosos en Israel, en el tiempo del profeta Eliseo, pero ninguno de ellos fue curado, sino Naamán, el sirio". Al oír estas palabras, todos los que estaban en la sinagoga se enfurecieron y, levantándose, lo empujaron fuera de la ciudad, hasta un lugar escarpado de la colina sobre la que se levantaba la ciudad, con intención de despeñarlo. Pero Jesús, pasando en medio de ellos, continuó su camino.……………….Además puedes escuchar el Evangelio diario en las siguientes plataformas:Spotify: https://open.spotify.com/show/2M0Ubx3Jh55B6W3b20c3GOApple podcast: https://podcasts.apple.com/us/podcast/evangelio-del-d%C3%ADa/id1590423907 Para más información puede consultar nuestro sitio: https://www.vozcatolica.com o escríbanos a info@vozcatolica.com .Si quiere colaborar con este Apostolado lo puede hacer dirigiéndose a: https://vozcatolica.com/ayudanos . Desde ya muchas gracias.

Commentaire de L'Évangile du jour Luc 4, 16-30 En ce temps-là, Jésus vint à Nazareth, où il avait été élevé. Selon son habitude, il entra dans la synagogue le jour du sabbat, et il se leva pour faire la lecture. On lui remit le livre du prophète Isaïe. Il ouvrit le livre et trouva le passage où il est écrit : L'Esprit du Seigneur est sur moi parce que le Seigneur m'a consacré par l'onction. Il m'a envoyé porter la Bonne Nouvelle aux pauvres, annoncer aux captifs leur libération, et aux aveugles qu'ils retrouveront la vue, remettre en liberté les opprimés, annoncer une année favorable accordée par le Seigneur. Jésus referma le livre, le rendit au servant et s'assit. Tous, dans la synagogue, avaient les yeux fixés sur lui. Alors il se mit à leur dire : « Aujourd'hui s'accomplit ce passage de l'Écriture que vous venez d'entendre » Tous lui rendaient témoignage et s'étonnaient des paroles de grâce qui sortaient de sa bouche. Ils se disaient : « N'est-ce pas là le fils de Joseph ? » Mais il leur dit : « Sûrement vous allez me citer le dicton : “Médecin, guéris-toi toi-même”, et me dire : “Nous avons appris tout ce qui s'est passé à Capharnaüm : fais donc de même ici dans ton lieu d'origine !” » Puis il ajouta : « Amen, je vous le dis : aucun prophète ne trouve un accueil favorable dans son pays. En vérité, je vous le dis : Au temps du prophète Élie, lorsque pendant trois ans et demi le ciel retint la pluie, et qu'une grande famine se produisit sur toute la terre, il y avait beaucoup de veuves en Israël ; pourtant Élie ne fut envoyé vers aucune d'entre elles, mais bien dans la ville de Sarepta, au pays de Sidon, chez une veuve étrangère. Au temps du prophète Élisée, il y avait beaucoup de lépreux en Israël ; et aucun d'eux n'a été purifié, mais bien Naaman le Syrien. » À ces mots, dans la synagogue, tous devinrent furieux. Ils se levèrent, poussèrent Jésus hors de la ville, et le menèrent jusqu'à un escarpement de la colline où leur ville est construite, pour le précipiter en bas. Mais lui, passant au milieu d'eux, allait son chemin. L'Amour Vaincra ! Fr. Paul Adrien d'Hardemare (op)  Et l'aventure continue ! retrouvez : les vidéos sur

Homilia Padre Reinaldo Satiro, IVE:Evangelho de Jesus Cristo segundo Lucas 4,16-30Naquele tempo,veio Jesus à cidade de Nazaré, onde se tinha criado. Conforme seu costume, entrou na sinagoga no sábado, e levantou-se para fazer a leitura.Deram-lhe o livro do profeta Isaías. Abrindo o livro, Jesus achou a passagem em que está escrito:"O Espírito do Senhor está sobre mim, porque ele me consagrou com a unção para anunciar a Boa-Nova aos pobres; enviou-me para proclamar a libertação aos cativos e aos cegos a recuperação da vista; para libertar os oprimidos e para proclamar um ano da graça do Senhor".Depois fechou o livro, entregou-o ao ajudante, e sentou-se.Todos os que estavam na sinagoga tinham os olhos fixos nele. Então começou a dizer-lhes: "Hoje se cumpriu esta passagem da Escrituraque acabastes de ouvir."Todos davam testemunho a seu respeito, admirados com as palavras cheias de encantoque saíam da sua boca. E diziam: "Não é este o filho de José?"Jesus, porém, disse: "Sem dúvida, vós me repetireis o provérbio: Médico, cura-te a ti mesmo. Faze também aqui, em tua terra, tudo o que ouvimos dizer que fizeste em Cafarnaum".E acrescentou: "Em verdade eu vos digo que nenhum profeta é bem recebido em sua pátria. De fato, eu vos digo: no tempo do profeta Elias, quando não choveu durante três anos e seis meses e houve grande fome em toda a região, havia muitas viúvas em Israel. No entanto, a nenhuma delas foi enviado Elias, senão a uma viúva que vivia em Sarepta, na Sidônia. E no tempo do profeta Eliseu, havia muitos leprosos em Israel. Contudo, nenhum deles foi curado,mas sim Naamã, o sírio".Quando ouviram estas palavras de Jesus,todos na sinagoga ficaram furiosos. Levantaram-se e o expulsaram da cidade.Levaram-no até ao alto do monte sobre o qual a cidade estava construída, com a intenção de lançá-lo no precipício.Jesus, porém, passando pelo meio deles,continuou o seu caminho. Palavra da Salvação.

Naquele tempo, 16 veio Jesus à cidade de Nazaré, onde se tinha criado. Conforme seu costume, entrou na sinagoga no sábado, e levantou-se para fazer a leitura. 17 Deram-lhe o livro do profeta Isaías. Abrindo o livro, Jesus achou a passagem em que está escrito: 18 "O Espírito do Senhor está sobre mim, porque ele me consagrou com a unção para anunciar a Boa-Nova aos pobres; enviou-me para proclamar a libertação aos cativos e aos cegos a recuperação da vista; para libertar os oprimidos 19 e para proclamar um ano da graça do Senhor". 20 Depois fechou o livro, entregou-o ao ajudante, e sentou-se. Todos os que estavam na sinagoga tinham os olhos fixos nele. 21 Então começou a dizer-lhes: "Hoje se cumpriu esta passagem da Escritura que acabastes de ouvir." 22 Todos davam testemunho a seu respeito, admirados com as palavras cheias de encanto que saíam da sua boca. E diziam: "Não é este o filho de José?" 23 Jesus, porém, disse: "Sem dúvida, vós me repetireis o provérbio: Médico, cura-te a ti mesmo. Faze também aqui, em tua terra, tudo o que ouvimos dizer que fizeste em Cafarnaum". 24 E acrescentou: "Em verdade eu vos digo que nenhum profeta é bem recebido em sua pátria. 25 De fato, eu vos digo: no tempo do profeta Elias, quando não choveu durante três anos e seis meses e houve grande fome em toda a região, havia muitas viúvas em Israel. 26 No entanto, a nenhuma delas foi enviado Elias, senão a uma viúva que vivia em Sarepta, na Sidônia. 27 E no tempo do profeta Eliseu, havia muitos leprosos em Israel. Contudo, nenhum deles foi curado, mas sim Naamã, o sírio". 28 Quando ouviram estas palavras de Jesus, todos na sinagoga ficaram furiosos. 29 Levantaram-se e o expulsaram da cidade. Levaram-no até ao alto do monte sobre o qual a cidade estava construída, com a intenção de lançá-lo no precipício. 30 Jesus, porém, passando pelo meio deles, continuou o seu caminho.

Muchos más recursos para tu vida de fe (Santo Rosario, Oración, etc.) en nuestra web https://sercreyente.com________________Lunes, 1 de septiembre de 2025 (22ª Semana del Tiempo Ordinario)Evangelio del día y reflexión... ¡Deja que la Palabra del Señor transforme tu vida! Texto íntegro del Evangelio y de la Reflexión en https://sercreyente.com/el-espiritu-del-senor-esta-sobre-mi/[Lucas 4, 16-30] En aquel tiempo, fue Jesús a Nazaret, donde se había criado, entró en la sinagoga, como era su costumbre los sábados, y se puso en pie para hacer la lectura. Le entregaron el rollo del profeta Isaías y, desenrollándolo, encontró el pasaje donde estaba escrito: «El Espíritu del Señor está sobre mí, porque él me ha ungido. Me ha enviado a evangelizar a los pobres, a proclamar a los cautivos la libertad, y a los ciegos, la vista; a poner en libertad a los oprimidos; a proclamar el año de gracia del Señor». Y, enrollando el rollo y devolviéndolo al que lo ayudaba, se sentó. Toda la sinagoga tenía los ojos clavados en él. Y él comenzó a decirles: «Hoy se ha cumplido esta Escritura que acabáis de oír». Y todos le expresaban su aprobación y se admiraban de las palabras de gracia que salían de su boca. Y decían: «¿No es este el hijo de José?». Pero Jesús les dijo: «Sin duda me diréis aquel refrán: “Médico, cúrate a ti mismo”, haz también aquí, en tu pueblo, lo que hemos oído que has hecho en Cafarnaún». Y añadió: «En verdad os digo que ningún profeta es aceptado en su pueblo. Puedo aseguraros que en Israel había muchas viudas en los días de Elías, cuando estuvo cerrado el cielo tres años y seis meses y hubo una gran hambre en todo el país; sin embargo, a ninguna de ellas fue enviado Elías sino a una viuda de Sarepta, en el territorio de Sidón. Y muchos leprosos había en Israel en tiempos del profeta Eliseo, sin embargo, ninguno de ellos fue curado sino Naamán, el sirio». Al oír esto, todos en la sinagoga se pusieron furiosos y, levantándose, lo echaron fuera del pueblo y lo llevaron hasta un precipicio del monte sobre el que estaba edificado su pueblo, con intención de despeñarlo. Pero Jesús se abrió paso entre ellos y seguía su camino.________________Descárgate la app de SerCreyente en https://sercreyente.com/app/¿Conoces nuestra Oración Online? Más información en: https://sercreyente.com/oracion¿Quieres recibir cada día el Evangelio en tu whatsapp? Alta en: www.sercreyente.com/whatsappTambién puedes hacer tu donativo en https://sercreyente.com/ayudanos/Contacto: info@sercreyente.com

+ Del Evangelio según san Lucas +En aquel tiempo, Jesús fue a Nazaret, donde se había criado. Entró en la sinagoga, como era su costumbre hacerlo los sábados, y se levantó para hacer la lectura. Se le dio el volumen del profeta Isaías, lo desenrolló y encontró el pasaje en que estaba escrito: El Espíritu del Señor está sobre mí, porque me ha ungido para llevar a los pobres la buena nueva, para anunciar la liberación a los cautivos y la curación a los ciegos, para dar libertad a los oprimidos y proclamar el año de gracia del Señor. Enrolló el volumen, lo devolvió al encargado y se sentó. Los ojos de todos los asistentes a la sinagoga estaban fijos en él. Entonces comenzó a hablar, diciendo: "Hoy mismo se ha cumplido este pasaje de la Escritura, que ustedes acaban de oír". Todos le daban su aprobación y admiraban la sabiduría de las palabras que salían de sus labios, y se preguntaban: "¿No es éste el hijo de José?" Jesús les dijo: "Seguramente me dirán aquel refrán: Médico, cúrate a ti mismo, y haz aquí, en tu propia tierra, todos esos prodigios que hemos oído que has hecho en Cafarnaúm ". Y añadió: "Yo les aseguro que nadie es profeta en su tierra. Había ciertamente en Israel muchas viudas en los tiempos de Elías, cuando faltó la lluvia durante tres años y medio, y hubo un hambre terrible en todo el país; sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda que vivía en Sarepta, ciudad de Sidón. Había muchos leprosos en Israel, en tiempos del profeta Eliseo; sin embargo, ninguno de ellos fue curado sino Naamán, que era de Siria". Al oír esto, todos los que estaban en la sinagoga se llenaron de ira, y levantándose, lo sacaron de la ciudad y lo llevaron hasta una barranca del monte, sobre el que estaba construida la ciudad, para despeñarlo. Pero él, pasando por en medio de ellos, se alejó de allí.Palabra del Señor.

Voici l'Évangile du lundi 1er septembre 2025 : « Il m'a envoyé porter la Bonne Nouvelle aux pauvres » (Lc 4, 16-30) En ce temps-là, Jésus vint à Nazareth, où il avait été élevé. Selon son habitude, il entra dans la synagogue le jour du sabbat, et il se leva pour faire la lecture. On lui remit le livre du prophète Isaïe. Il ouvrit le livre et trouva le passage où il est écrit : L'Esprit du Seigneur est sur moi parce que le Seigneur m'a consacré par l'onction. Il m'a envoyé porter la Bonne Nouvelle aux pauvres, annoncer aux captifs leur libération, et aux aveugles qu'ils retrouveront la vue, remettre en liberté les opprimés, annoncer une année favorable accordée par le Seigneur. Jésus referma le livre, le rendit au servant et s'assit. Tous, dans la synagogue, avaient les yeux fixés sur lui. Alors il se mit à leur dire : « Aujourd'hui s'accomplit ce passage de l'Écriture que vous venez d'entendre » Tous lui rendaient témoignage et s'étonnaient des paroles de grâce qui sortaient de sa bouche. Ils se disaient : « N'est-ce pas là le fils de Joseph ? » Mais il leur dit : « Sûrement vous allez me citer le dicton : “Médecin, guéris-toi toi-même”, et me dire : “Nous avons appris tout ce qui s'est passé à Capharnaüm : fais donc de même ici dans ton lieu d'origine !” » Puis il ajouta : « Amen, je vous le dis : aucun prophète ne trouve un accueil favorable dans son pays. En vérité, je vous le dis : Au temps du prophète Élie, lorsque pendant trois ans et demi le ciel retint la pluie, et qu'une grande famine se produisit sur toute la terre, il y avait beaucoup de veuves en Israël ; pourtant Élie ne fut envoyé vers aucune d'entre elles, mais bien dans la ville de Sarepta, au pays de Sidon, chez une veuve étrangère. Au temps du prophète Élisée, il y avait beaucoup de lépreux en Israël ; et aucun d'eux n'a été purifié, mais bien Naaman le Syrien. » À ces mots, dans la synagogue, tous devinrent furieux. Ils se levèrent, poussèrent Jésus hors de la ville, et le menèrent jusqu'à un escarpement de la colline où leur ville est construite, pour le précipiter en bas. Mais lui, passant au milieu d'eux, allait son chemin.   Cet enregistrement est proposé bénévolement pour répandre la Parole de Dieu

Lucas 4, 16-30En aquel tiempo, Jesús fue a Nazaret, donde se había criado, entró en la sinagoga, como era su costumbre los sábados, y se puso en pie para hacer la lectura. Le entregaron el rollo del profeta Isaías y, desenrollándolo, encontró el pasaje donde estaba escrito:«El Espíritu del Señor está sobre mí, porque él me ha ungido. Me ha enviado a evangelizar a los pobres, a proclamar a los cautivos la libertad, y a los ciegos, la vista; a poner en libertad a los oprimidos; a proclamar el año de gracia del Señor».Y, enrollando el rollo y devolviéndolo al que lo ayudaba, se sentó. Toda la sinagoga tenía los ojos clavados en él.Y él comenzó a decirles:«Hoy se ha cumplido esta Escritura que acabáis de oír».Y todos le expresaban su aprobación y se admiraban de las palabras de gracia que salían de su boca.Y decían:«¿No es el hijo de José?».Pero Jesús les dijo:«Sin duda me diréis aquel refrán: “Médico, cúrate a ti mismo”, haz también aquí, en tu pueblo, lo que hemos oído que has hecho en Cafarnaún».Y añadió:«En verdad os digo que ningún profeta es aceptado en su pueblo. Puedo aseguraros que en Israel había muchas viudas en los días de Elías, cuando estuvo cerrado el cielo tres años y seis meses y hubo una gran hambre en todo el país; sin embargo, a ninguna de ellas fue enviado Elías sino a una viuda de Sarepta, en el territorio de Sidón. Y muchos leprosos había en Israel en tiempos del profeta Eliseo, sin embargo, ninguno de ellos fue curado sino Naamán y el sirio».Al oír esto, todos en la sinagoga se pusieron furiosos y, levantándose, lo echaron fuera del pueblo y lo llevaron hasta un precipicio del monte sobre el que estaba edificado su pueblo, con intención de despeñarlo.Pero Jesús se abrió paso entre ellos y seguía su camino.

La vida no se mide en décadas o en grandes logros, sino en la fidelidad de cada día. Dios habló de los “muchos días” de Elías en Sarepta para recordarnos que la vida se construye paso a paso, con disciplina diaria en la oración, en la Palabra y en la obediencia. El futuro de tu matrimonio, tus hijos, tu salud y tus finanzas se decide en lo que haces hoy. Aprende a vivir un día a la vez y a contar tus días con sabiduría para que cada jornada glorifique a Dios.

La viuda de Sarepta había visto un milagro, pero cuando su hijo murió culpó a Elías y hasta a Dios. El profeta no discutió: llevó al niño a su lugar secreto y clamó al Señor. Dios lo resucitó, y entonces la mujer declaró: “Ahora sé que eres un hombre de Dios”. La fe verdadera se reconoce no solo por lo que decimos, sino por cómo vivimos y cómo confiamos en el Dios vivo. ¿Pueden los que están cerca de ti ver a Cristo en tu vida?

La historia de la viuda de Sarepta nos enseña que la obediencia a Dios siempre va acompañada de fe. Elías llegó a una mujer que solo tenía un puñado de harina y un poco de aceite para preparar su última comida, pero obedeció la palabra del profeta y confió en Dios. El resultado fue un milagro: nunca faltó alimento en su casa. Así es el camino de la fe: no se basa en lo que vemos, sino en la fidelidad del Dios vivo. ¿Quieres ver milagros en tu vida? Empieza a obedecer, aunque parezca imposible.

En 1 Reyes 17:8-10, Dios lleva a Elías a una nueva etapa: Sarepta de Sidón, un lugar extraño, difícil y lleno de retos. Allí no sería sustentado por un rico, sino por una viuda extranjera en medio de la escasez. El arroyo se había secado, pero Dios tenía un plan de refinamiento, para enseñarle que la provisión no depende de recursos visibles, sino de la obediencia y confianza absoluta en Él. Este pasaje nos recuerda que no debemos apresurarnos ni ir más rápido que Dios; su tiempo siempre es perfecto, y su provisión nunca falla.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über Börsen-Non-Event Alaska, eine hoffnungsvolle Softwarestudie mit 6 Top Picks und einen neuen Chart of Doom. Außerdem geht es um CoreWeave, Salesforce, Siemens Energy, Cisco Systems, Palo Alto Networks, ProSiebenSat.1, Novo Nordisk, AstraZeneca, AbbVie, Siemens Healthineers, Sonova, Medtronic, Haleon, iShares Aging Population ETF (WKN: A2ANH1), Boston Scientific, Glaukos, Exelixis, Sarepta, Swisscanto Healthy Longevity Fund (WKN: A40L0T), Eli Lilly, Abbott, UnitedHealth, Microsoft, Amazon, Nvidia, Meta, Netflix, Coreweave, Oracle, Carvana, TSMC, Roblox, Crowdstrike, Opendoor Technologies, Alibaba, PDD, Petroleo Brasileiro, Teva Pharmaceutical, Robinhood, Northrop Grumman, RTX, Lululemon, Mercadolibre, Talen Energy, GE Vernova, Broadcom, Vistra, Micron, Alphabet, Somnigroup International, Flutter Entertainment. Und hier gibt es die Tickets zum Finance Summit am 17. September! https://veranstaltung.businessinsider.de/FinanceSummit Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

A través del Pastor: Jose HuancaFecha: 17 de Marzo del 2025Desde la Iglesia : Tabernáculo de SalvaciónLugar: Desde Cochabamba- Bolivia hasta el lugar donde usted está.Comunícate y conéctate con nosotros a través de Facebook y la página webBolivia pequeña entre las naciones de ti saldrá la "Luz a las Naciones"facebook.com/tabernaculodesalvacionfacebook.com/escueladecristoenboliviaApp de Radio: Red Pentecostés Online:Para Android: https://play.google.com/store/apps/details?id=com.fexred.redpentecostesPara ios (iphone): https://apps.apple.com/es/app/id6473747619www.edcnaciones.org

On this week's episode, Josh Schimmer, Eric Schmidt, and Tess Cameron kick off with policy, discussing Vinay Prasad's return to the FDA and the implications for the biotech industry. The conversation turns to NIH's Jay Bhattacharya, who attributed the decline in public trust in mRNA vaccines to perception rather than safety or efficacy, citing this as the reason to curtail funding. In market trends, the co-hosts discuss investor blind spots, specifically near-term product launches. Next, the group examines whether rising drug prices are sustainable and the six-month IPO drought. They also debate how non-commercial companies approach earnings calls, pointing to Summit Therapeutics' choice to skip its Q2 call and whether most development-stage biotechs should follow suit. ARS Pharmaceuticals' earnings/epinephrine nasal spray launch and RTW Investments deal with Aquestive Therapeutics are also overviewed. The episode concludes with data news, covering Insmed's lung disease approval and Sarepta's safety update. *This episode aired on August 15, 2025.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sarepta has released new safety data for their gene therapy Elevidys, showing zero ambulatory deaths in patients with Duchenne muscular dystrophy. This data confirms the therapy's positive risk/benefit profile. Meanwhile, Novo Nordisk's rapid rise and fall was driven by GLP-1s like Ozempic and Wegovy, leading to a plummet in stock value. Insmed has received FDA approval for the first bronchiectasis drug and DPP1 blocker, Brinsupri. Texas has accused Eli Lilly of "bribing" prescribers to push their drugs Mounjaro and Zepbound, leading to a new lawsuit. Genscript is entering a new era of innovation and trust, offering exclusive promos and events. Additionally, Tang Capital is on a buyout binge in the biotech industry, while a top ARPA-H official has departed in protest of cuts to mRNA funding. The biotech industry continues to see contractions with companies like AbSci, Fate, and Oric downsizing. In career advice, loyalty is seen as a flawed strategy that can cost individuals opportunities.Arrowhead, a biotech company, has emerged as a savior in the RNA interference (RNAi) pipeline after Sarepta faced troubles unrelated to Arrowhead's assets. Concentra Biosciences, a biotech shell company, has been on a buying spree, acquiring four biotechs in the past month and seven so far this year. President Trump's most favored nation drug pricing policy is seen as unfavorable for all parties involved. Novo Nordisk experienced a rapid rise and fall due to the success of ozempic and wegovy. Lilly is facing drug pricing pressure while defending its injectable GLP-1 empire. Novartis is rumored to be considering acquiring RNA specialist Avidity. Despite safety concerns, Sarepta beat Q2 estimates, but not due to sales of its product Elevidys. Various biotech companies are downsizing while others are receiving significant investments.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Bayer has secured a $1.3 billion deal with Kumquat Biosciences for exclusive access to their small-molecule KRAS G12D blocker. Meanwhile, Arrowhead has navigated through the Sarepta storm and experienced a drop in stock prices, despite having no direct ties to Sarepta's issues. In other news, a medical journal stands firm in refusing to retract a vaccine study, HHS has put a freeze on Vaxart's oral COVID-19 vaccine, and GenScript is celebrating a new era of innovation.## Additionally, discussions surround obesity leaders defending their injectable GLP-1 empires, recent layoffs at Merck, and the hurdles faced by oral obesity drugs. Opinion pieces delve into the skepticism towards mRNA technology and the potential repercussions of dismissing the head maha implementor following an mRNA purge. Stay tuned for more updates on upcoming events and job opportunities in the industry.

Vinay Prasad is back at the FDA as chief of the FDA's Center for Biologics Evaluation and Research. Prasad's return—which hit the news wires Saturday morning—came just 10 days after his unexpected exit on July 29, following blowback over the saga involving Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy Elevidys, and a campaign by conversative personalities to oust the outspoken physician.Elsewhere in the government, Gray Delany, former head of HHS' and President Donald Trump's Make America Healthy Again agenda, has been fired—days after Health and Human Services Secretary Robert F. Kennedy Jr. axed 22 mRNA vaccine contracts under the Biomedical Advanced Research and Development Authority. Delany's ouster came after he allegedly butted heads with other agency officials over how announcements were made, according to reporting from Endpoints News. The mRNA contract cuts, meanwhile, have sparked criticism from the scientific community and concern that the growing anti-mRNA sentiment could also have a negative effect on research for cancer therapeutics.In somewhat related news, the Annals of Internal Medicine is refusing to retract a large-scale study it ran in July that pointed to the lack of an association between childhood aluminum exposure through vaccination and chronic conditions, despite Kennedy's criticism. In an op-ed published earlier this month, the Health Secretary took issue with the study's design.In obesity news, biopharma darling Eli Lilly suffered a rare chink in its normally impenetrable GLP-1 armor. The first Phase III trial for oral weight loss therapy orforglipron read out last week, and the results were underwhelming, at least to Wall Street. Truist Securities wrote that the data support approval but “leaves room for competition.” This is good news for a whole host of companies, including Roche, Viking, Terns and Rhythm Pharmaceuticals, who all have weight loss pills at various stages of development.And in gene therapy, the hits just keep coming. The FDA has limited the use of bluebird bio's gene therapy Skysona to patients with cerebral adrenoleukodystrophy for whom no other therapies or stem cell donors are available, due to a heightened risk of blood cancers. This follows safety issues in gene therapy trials experienced by Allogene, and, of course, Sarepta Therapeutics. This week in ClinicaSpace, Dan Samorodnitsky explored the future of AAV technology. And in BioPharm Executive, Annalee Armstrong sat down with Chris Anzalone, CEO of Arrowhead Pharmaceuticals—Sarepta's key strategic partner—to learn how his company has been weathering the storm.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vinay Prasad has returned to his position as director of the Center for Biologics Evaluation and Research at the FDA after a sudden exit less than two weeks ago. The FDA has restricted the patient pool for bluebird's Skysona gene therapy due to safety concerns, and Sarepta's AAV gene therapy platform has come under scrutiny following patient deaths from liver injuries. Genscript is celebrating a new era of innovation and trust.The text discusses the scrutiny faced by AAV gene therapy technology following patient deaths related to Sarepta Therapeutics' platform. There is a push for improvement in the technology, while some are looking to move on to other options. The article also highlights the importance of mRNA technology in cancer research and the need for continued investment in this area. Additionally, it mentions the FDA's decision on Biogen and Eisai's Alzheimer's drug, as well as five oral obesity drugs that could rival Lilly's Orforglipron. Other topics covered include cancer drug developments, gene therapy news, and upcoming industry events.Stay tuned for more updates on the latest news in the pharmaceutical and biotechnology industries.

On this week's episode, Daphne Zohar, Josh Schimmer, Brian Skorney, Paul Matteis, Sam Fazeli, Brad Loncar, and Matt Gline cover top news surrounding Trump's pricing letters to 17 major pharma companies demanding U.S. price cuts on new drugs, and the relevance to his MFN initiative. They also touch on Dr. Mehmet Oz's meetings with biotech leaders in D.C. and looming tariff risks. The group discusses Vinay Prasad's departure from CBER, opining on implications for biotech, and sharing insights from the CEO listening session with Marty Makary and George Tidmarsh. Next, they review the latest Sarepta news, including Vinay Prasad's response to the patient deaths and broader credibility themes. To close out the regulatory discussion, RFK Jr.'s proposal to overhaul the Vaccine Injury Compensation Program (VICP) is discussed. In deals and restructuring news, the co-hosts unpack the GSK-Hengrui partnership amid China outlicensing trends, BMS/Bain's new spinout company, Galapagos's restructuring plans, and AbbVie's reportedly targeting a $1B buyout of Gilgamesh. They also highlight drug launch momentum, with strong quarters from Alnylam, Argenx, and Neurocrine, challenging the “shorting the launch” thesis. The conversation shifts to data with Roche's Alzheimer's updates and expectations around Lilly's abeta prevention study, touching on implications for the anti-amyloid class and Biogen's outlook, including rising use of blood-based biomarkers and earnings commentary. They also discuss Compass's regulatory strategy for psychedelics. The episode concludes with each co-host reflecting on market sentiment and the industry's current state. *This episode aired on August 1, 2025.

On this week's episode, Eric Schmidt, Paul Matteis, Sam Fazeli, and Brian Skorney begin with a recap of the week's Sarepta news, covering their initial refusal then agreement to pause Elevidys shipments, if it can return to the market, the broader lessons for the biotech industry, and the communication breakdown between Sarepta and the FDA. Continuing with regulatory news, the group discusses the appointment of George Tidmarsh as the new CDER director and his role within FDA leadership. The conversation then turns to Replimune's CRL for RP1 melanoma, Prasad's likely influence in the rejection, and the impact on the investment community. In data news, the group overviews Alkermes' positive Phase 1 data for its orexin 2 receptor agonist for type 1 narcolepsy, along with the safety controversy, and Abivax's Phase 3 ulcerative colitis data and stock spike. Prime Medicine's decision to reprice shares and strategies for better talent retention is also highlighted. The episode concludes with a brief overview of first-half 2025 licensing data, Roche earnings, and AstraZeneca's $50 billion U.S. investment. *This episode aired on July 25, 2025.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly is facing significant drug pricing pressure, with issues ranging from the pricing of their weight loss pill Orfoglipron to market battles with competitors like Novo Nordisk. Despite the challenges, Lilly's executives see opportunities for their products in the real world. Jazz Pharmaceuticals received FDA approval for Dordaviprone, making it the first new treatment for an ultra-rare brain tumor. In other news, Sarepta beat Q2 estimates despite not holding an investor call, and Trilink Biotechnologies is offering process development services for nucleic acid therapeutic development. Lotte Biologics is expanding its global CDMO operations, while a big pharma-backed mRNA startup raised $153 million in funding. Novo Nordisk's new CEO is focusing on obesity and diabetes, Pfizer is in talks with Trump on most favored nation drug pricing, and Bayer expects more layoffs. These developments in the pharma and biotech world showcase the ongoing challenges and opportunities in the industry. Stay tuned for more updates on the latest news and trends in this rapidly evolving sector.

It's nearly impossible to discuss the private health insurance landscape in America without referencing the killing of UnitedHealthcare CEO Brian Thompson last December.The shooting unleashed a wave of antipathy directed at insurers and brought deep-seeded, longstanding grievances against these for-profit health entities to the fore.In the intervening months, UnitedHealth Group and the broader insurer class have suffered significant damage not only to their respective bottom lines, but also their corporate reputations.Given the current state of play, we wanted to hear how medical marketers are navigating this uniquely challenging situation.Reporter Heerea Rikhraj speaks with Shannon Langrand, CEO of her namesake agency, about how health insurers are being marketed in 2025 as well as what challenges are lingering in the payer space.For our Trends segment, we parse through the Sarepta Therapeutics saga and pull out some key takeaways. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

Center for Drug Evaluation and Research Head George Tidmarsh will oversee the Center for Biologics Evaluation and Research on an acting basis after Vinay Prasad's abrupt departure hours after the recording of last week's episode of The Weekly. While the situation is being billed as temporary, rumors are swirling that structural changes may be afoot at the FDA with Commissioner Marty Makary looking for better drug, biologic alignment.Meanwhile, the agency has come under criticism for another recent decision—one apparently driven by CDER's Oncology Center of Excellence director Richard Pazdur: the rejection of Replimmune's advanced melanoma drug, RP1. According to reporting by multiple outlets, Pazdur opposed the consensus opinion of CBER staff to approve the drug. The research team behind Replimmune's Phase III study penned an open letter to the FDA on Friday responding to the issues outlined in the agency's complete response letter. Meanwhile, the FDA's Sarepta saga continues, highlighting “unprecedented” FDA leaks and a veritable communications disaster.On the business side of biopharma, Q2 earnings continue to unfurl, with Pfizer, Vertex, BioNTech, Merck and Moderna all reporting this past week. Merck's $3 billion savings push has claimed 6,000 jobs, contributing to a brutal July that saw the entire biopharma industry axe 7,900 employees, a 487% year-over-year increase, based on BioSpace tallies. Meanwhile, Pfizer CEO Albert Bourla confirmed he has been in direct contact with President Donald Trump to negotiate a path forward on Most Favored Nation drug pricing after the president sent letters to 17 Big Pharma companies—and posted on his Truth Social platform—asking them to comply with the policy within 60 days or face potential unspecified consequences.In other policy news, the Centers for Medicare and Medicaid Services is reportedly considering coverage of GLP-1 drugs for weight management and obesity—reviving a Biden era proposal the Trump admin scrapped earlier this year.Finally, in BioPharm Executive this week, we have a special report on the situation in China as international drugmakers swoop into the region to find new drug candidates, while other companies build their therapeutic farm systems from incubators and venture arms. And check out BioSpace's brand new Manufacturing Brief, where we bring you the latest news and analysis in the area of biopharma manufacturing, starting with a feature on how to make cell and gene therapies commercially viable.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. BioNTech is focusing on infectious diseases as vaccine rates drop, with expectations that the US COVID-19 vaccination rate will decrease slightly. Glioblastoma research is seeing increased funding and interest from companies like Merck and Jazz Pharmaceuticals. The FDA's rejection of Replimmune's melanoma drug, despite staff consensus, has caused a drop in the company's stock. Sarepta and Capricor learned of regulatory decisions through media leaks, causing confusion for patients and families. Trilink Biotechnologies offers process development services for nucleic acid therapeutic development. Lotte Biologics is expanding globally, Allogene is discontinuing an immunosuppressive antibody after a patient death, and NIH funding cuts are impacting biotech. Pharmas are increasing investment in AI despite challenges in the industry. Trump urges pharma companies to address drug pricing, while Merck plans to cut 6,000 jobs to save $3 billion.

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple patient deaths. In this week’s episode of "The Top Line," we explore Sarepta’s brief standoff with the FDA over Elevidys, a short-lived marketing pause, and the regulator’s surprise reversal on the treatment. Fierce Pharma’s Fraiser Kansteiner and Angus Liu sit down with Fierce Biotech’s Gabrielle Masson to recap the story and discuss the broader implications the Elevidys saga may have for gene therapy, the FDA and the pharmaceutical industry. To learn more about the topics in this episode: Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Sarepta, bowing to FDA pressure, pauses shipments of Duchenne gene therapy Elevidys FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe See omnystudio.com/listener for privacy information.

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

Howie and Harlan discuss Dr. Vinay Prasad's departure from the FDA after a backlash against his decisions on Sarepta's Duchenne muscular dystrophy gene therapy. Also examined: AI in clinical settings, changes in NIH grantmaking, and the 60th anniversary of Medicare and Medicaid. Links: Sarepta and the FDA “STAT breaks down the confusing, heartbreaking Sarepta saga” “Sarepta Therapeutics' Duchenne therapy faces ‘arduous' path back to market, senior FDA official says” “For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak” “FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault” “FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients” “FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients” “Controversial FDA official Dr. Vinay Prasad departs agency” “Top F.D.A. Vaccine Official Resigns, Citing Kennedy's ‘Misinformation and Lies'” “Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag” “Timeline: The Rise and Fall of Vioxx” “What have we learnt from Vioxx?” THC in pizza dough “C.D.C. Ties 85 Cases of THC-Related Symptoms to Wisconsin Restaurant” “Tetrahydrocannabinol Intoxication from Food at a Restaurant — Wisconsin, October 2024” NIH funding “NIH is shrinking the number of research projects it funds due to a new Trump policy” NIH: Supporting Fairness and Originality in NIH Research Applications “Fearful of AI-generated grant proposals, NIH limits scientists to six applications per year” “Trump budget draft proposes NIH consolidation and 40% spending cut” Raw milk “Outbreak of Salmonella Typhimurium Infections Linked to Commercially Distributed Raw Milk — California and Four Other States, September 2023–March 2024” “The Dangers of Raw Milk: Unpasteurized Milk Can Pose a Serious Health Risk” AI in healthcare update “Ambience Healthcare Announces $243 Million Series C to Scale its AI Platform for Health Systems” “As ambient scribes face off, Doximity lures doctors with a free option” Aidoc: “AI Empowering Radiologists” “Clinical Implementation of a Combined Artificial Intelligence and Natural Language Processing Quality Assurance Program for Pulmonary Nodule Detection in the Emergency Department Setting” “Large Language Models as an Inexpensive and Effective Extra Set of Eyes in Radiology Reporting” “Current Trends in Remote and Flexible Work Options in Radiology and Perception of Impact on Radiologist Well-being” Medicare and Medicaid 60th anniversary CMS' program history “Medicare and Medicaid turn 60 – and face historic cuts decades in the making” UnitedHealth and Medicare Advantage “UnitedHealth says 2025 earnings will be worse than expected as high medical costs dog insurers” “UnitedHealthcare to exit certain Medicare Advantage markets as costs balloon, impacting 600K enrollees” “Novo Nordisk slides further on US competition, new CEO concerns” “Dems Must Really Fix Medicaid, Not Just Undo Trump's Damage to It”   Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the top biopharma venture capital raises of H1 2025 are summarized. Despite challenges like layoffs and market fluctuations, GSK remains committed to investing in the US despite tariffs. Other headlines include Madrigal's potential $2 billion investment, Biogen and Eisai's Alzheimer's drug update, and Novo Nordisk's new leadership. Trilink Biotechnologies is offering self-amplifying RNA constructs for potential therapeutic advancements.AI biotech companies have secured substantial funding in the first half of 2025, with continued investment pouring into startups within the industry. The top five biopharma venture capital raises of this period are highlighted. There is confusion surrounding Ira's definition of 'drug,' potentially hindering companies from pursuing approval for new formulations and indications. Vinay Prasad's departure from the FDA's Center for Biologics Evaluation and Research, following controversies related to Sarepta, has raised concerns among developers. Despite challenges, four biotech companies are successfully launching their products independently.Over 260 million people are impacted by rare diseases, emphasizing the need for faster evidence generation through global real-world data. GSK's commitment to investing in the US, Merck's cost-cutting measures to support its launch schedule, and Novo Nordisk's new leadership are also highlighted. The FDA has updated regulations regarding Sarepta's DMD gene therapy, making it available for ambulatory patients. Adaptimmune anticipates significant staff reductions following a cell therapy asset sale. Stay tuned for more updates on the latest developments in the biopharma industry.

The morning after the FDA's vaccine regulator Dr. Vinay Prasad announced his resignation, FDA Commissioner Dr. Marty Makary shares the agency's position on the measles vaccine, Sarepta's Duchenne therapy, and the addictive kratom-derived compound OH-7. Booking Holdings CEO Glenn Fogel discusses the impact of geopolitics on travel to the U.S. While Canadians and Europeans are still traveling, the operator of Agoda, Priceline, and Kayak says they're going to Mexico and Asia, instead of the U.S. Plus, Wall Street remembers the lives lost in Monday's shooting, the first tsunami waves from Russia's 8.8 earthquake have hit Hawaii's shores, and CNBC's Eamon Javers reports on his conversation with Treasury Secretary Scott Bessent about trade talks with China. Eamon Javers - 07:24Dr. Marty Makary - 18:51Glenn Fogel - 36:48 In this episode:Eamon Javers, @EamonJaversJoe Kernen, @JoeSquawk Becky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.

The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company's Duchenne muscular dystrophy gene therapy be lifted for ambulatory patients, after determining that the death of an 8-year-old Brazilian Duchenne patient who had received Elevidys' was not caused by the drug.  Sarepta's stock has swung wildly and its transparency questioned after it elected not to reveal the death of a third patient—a participant in a trial of a gene therapy for limb girdle muscular dystrophy—during a business update last week.    Speaking of entities—or individuals—who have trouble staying out of the news, Health Secretary Robert F. Kennedy Jr. plans to dissolve the U.S. Preventive Services Task Force because it is “too woke.” Also on Monday, Kennedy addressed what he called the “broken” vaccine injury compensation program. Without offering details, he vowed to “fix” the U.S.'s VICP and return it to its “original Congressional intent.”   On the business side of the biopharma house, Q2 earnings are in full swing, with AstraZeneca announcing estimate-beating numbers and CEO Pascal Soriot saying the world “needs to share” in global pharma R&D, while Merck cut $3 billion to support an aggressive launch schedule. Meanwhile, a week ahead of its own earnings report, Novo Nordisk named a new CEO and lowered its 2025 sales guidance for the second time this year.   In clinical development, the Alzheimer's Association Annual Conference is underway in Toronto, with Roche's trontinemab the standout so far. In a Phase Ib/IIa trial, the next-gen anti-amyloid antibody rapidly cleared amyloid from the brains of patients with Alzheimer's disease after just seven months—besting the 18-month timeframe for Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. While Leqembi and Kisunla have shown some progress is slowing down the progression of Alzheimer's, their effect size is modest and they don't work for all patients—leaving plenty of room for symptomatic treatments, such as those being developed by Bristol Myers Squibb and Acadia Pharmaceuticals. The space is gearing up for several readouts, for both symptomatic and disease-modifying therapies alike.   And in BioPharm Executive this week, we dig into the top VC rounds so far this year and highlight a few scrappy biotechs walking the solo road.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 25, 2025. In this episode: Sanofi's Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech's Columvi; and an interview with Novavax. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-U4IN5X7DRVFLVIBJ4Q72VTAJUY/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The European Medicines Agency's CHMP did not recommend approving Elevidys for ambulatory patients with Duchenne muscular dystrophy, dealing a blow to Sarepta. FDA is rumored to request new data for Elevidys, leading to uncertainty as FDA considers a new study for the drug. In other news, Eli Lilly commits $856 million to Gate Bioscience for a new class of medicines, while Rocket trims headcount and pipeline focus. Roche also drops an early obesity asset as layoffs continue in the biopharma industry, with companies like Adicet optimizing their pipelines. Novartis makes a billion-dollar drug discovery deal with Matchpoint, and the FDA opens a pilot run of the commissioner voucher program.Stay tuned for more updates on the latest developments in the pharmaceutical and biotech world.

The end of a huge week for earnings and record highs on the S&P: Carl Quintanilla, Sara Eisen, and David Faber reacted to breaking commentary from President Trump top of the hour, before getting Apollo Global Chief Economist Torsten Slok's take… who's warning of stagflation ahead tied to tariffs: arguing there's “no free lunch”. Big Tech a key part of the recent rally – longtime investor Dan Niles broke down his top picks ahead of results next week from Apple, and why he sees clouds on the horizon come September. Plus: a number of individual stock movers… The team discussed what's driving huge declines in shares of Charter and Sarepta, Volkswagen's latest warning on tariffs – and what it means for the rest of the automakers, and new numbers out of one luxury retailer who's down big on the year.   

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs discuss the issues awaiting George Tidmarsh, the new director of the US Food and Drug Administration's Center for Drug Evaluation and Research (:24), as well as the next steps for the agency and Sarepta amid the ongoing problems with its gene therapy Elevidys (delandistrogene moxeparvovec) (23:49). More On These Topics From The Pink Sheet Will Tidmarsh's Industry Experience Translate As US FDA's Chief Drug Regulator?: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/breaking-news-pharma-ceo-george-tidmarsh-named-director-of-us-fdas-drug-center-2HXJJCPAIVB2RFNGDDU5NZVNQQ/ Business Background Of New CDER Director George Tidmarsh: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/business-background-of-new-cder-director-george-tidmarsh-BROCYQDUYFE3LIQDJ2JNBDWD6Y/ US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-cancer-reviewers-heading-for-the-exits-potentially-impacting-review-timelines-YMOFTXDFDZBGVGBIKFXHJY5XTY/ US FDA's Biologics Center Departures Grew Before More Than 100 RIFs Exited: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-biologics-center-departures-grew-before-more-than-100-rifs-exited-2LR3ZFYOBND3DLIWXSFFWWLFYE/ After Sarepta Reversed Course On Elevidys, Could An Adcomm Be Next?: https://insights.citeline.com/pink-sheet/product-reviews/post-marketing-regulation-and-studies/after-sarepta-reversed-course-on-elevidys-could-an-adcomm-be-next-ZA5ODQB3DJF4LBDFODMB52DM3M/ Sarepta Refuses To Stop Elevidys Shipments After Third Death Linked To Gene Therapy Vector: https://insights.citeline.com/pink-sheet/advanced-technologies/cell-and-gene-therapies/us-fda-asks-sarepta-to-stop-elevidys-shipments-after-third-death-linked-to-gene-therapy-vector-GLJ2YJDJGNBPLD3SSKKE6UVM34/

Elevidys shipments paused following third death; FDA committee votes against brexpiprazole combo for PTSD; Rapiblyk now available for SVT; sleep apnea pill looks promising; JUUL e-cigarettes gain marketing authorization.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

Howie and Harlan are joined by public health communicator Katelyn Jetelina for updates on COVID-19 and other issues, and to discuss how her emails to students and colleagues in the early days of the pandemic turned into a platform with global reach. Harlan looks at how AI is being used on both sides of the battle between providers and insurers over claims; Howie reports on a setback with a promising gene therapy for Duchenne muscular dystrophy. Links: Insurance Claims, AI, and Wearables “Elevance Health Reports Second Quarter 2025 Results” “Elevance lowers profit outlook, warns things will get worse for health insurers ““Blue KC wrongfully denied medical diagnoses, hospital alleges in AI-driven claims lawsuit” “Oscar Health cuts full-year guidance, estimates 2025 loss as ACA marketplace stumbles” Whoop “WHOOP Delivers Innovative Blood Pressure Insights for a Deeper Look at Your Well-Being” “Introducing Heart Screener: A smarter way to stay connected to your heart health” “Whoop says FDA is ‘overstepping its authority' with warning about blood pressure feature” FDA: WARNING LETTER, WHOOP, Inc. “RFK Jr. wants everyone to use wearables. What are the benefits, risks?” “Apple to Sell Watches With Blood-Oxygen Feature Disabled After Legal Setback” Your Local Epidemiologist Your Local Epidemiologist “Poll: Trust in Public Health Agencies and Vaccines Falls Amid Republican Skepticism” “Popular epidemiologist lays out future path of public health communication” Yale School of Public Health: PopHIVE Katelyn Jetelina: “NIH: The quiet engine of science is being dismantled” Katelyn Jetelina: “Covid-19 in pockets, sugar cane isn't better, ticks march on, rescission cuts (vs. everything else), bright spots, and more” Mayo Clinic: Norovirus infection Katelyn Jetelina: “The show must go on...” Katelyn Jetelina: “Harassment against scientists is out of control” Katelyn Jetelina: “Medicaid cuts: The how and why” CDC: H5 Bird Flu: Current Situatio CDC: Current Epidemic Trends (Based on Rt) for States” CDC: Measles Cases and Outbreaks Treating Duchenne Muscular Dystrophy Cleveland Clinic: Duchenne Muscular Dystrophy (DMD) “FDA approves Sarepta's Duchenne gene therapy for nearly all patients” “AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial” “Patient dies in Sarepta gene therapy trial, adding to safety concerns” “FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths” “In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy” “Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has initiated a voucher program to address lower drug prices and boost domestic investment, with up to five companies being selected based on national priorities. Roche has halted shipments of Sarepta's Elevidys gene therapy after reports of patient deaths. Sarepta is under FDA scrutiny following a third patient death, while the agency welcomes a new top drug regulator and rejects multiple new drugs from entering the market. Insights from women in biopharma highlight the importance of resilience. Zhen Li, an engineer, is playing a crucial role in shaping the field of siRNA. Research suggests that GLP-1s may offer protection against neurodegenerative diseases. Dispatch Bio enters the scene with a substantial $216 million investment for universal CAR T therapy. Sarepta complies with an FDA request to suspend US shipments of Elevidys, raising concerns about transparency and impacting the company's reputation. Replimune experiences a significant drop in stock value following an FDA rejection, while AstraZeneca makes a bold $50 billion investment in US manufacturing to prepare for potential tariffs. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the industry.

Last week's public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene therapy Elevidys, a move the biotech has resisted. The deaths, and disputes between FDA and Sarepta, raise questions about the future of AAV gene therapies, as well as the future of FDA's platform technology designation. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the events surrounding Sarepta's gene therapies and discuss how FDA, industry and patient groups should come together to learn the lessons from the tragic, avoidable deaths.BioCentury's analysts also assess Monday's appointment of Stanford professor and biotech executive George Tidmarsh to lead FDA's Center for Drug Evaluation and Research, and check in on the latest trends in venture financings. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656537#biotech #biopharma #pharma #lifescience #GeneTherapy #AAVTherapy #Sarepta #Elevidys00:01 - Sponsor Message: IQVIA Biotech02:03 - Gene Therapy17:59 - Leading CDER27:00 - Venture ReportTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 18, 2025. In this episode: – J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China's mid-cap companies thrive; and a look behind Glenmark's landmark trispecific deal. Article links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HYQOHZ42CNCQRPF6HCKGLTHUKM/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

Google riding high ahead of earnings, with potential for its longest win streak in years. Japan's election results have the Yen strengthening against the dollar. And Sarepta's slide continues as the drug developer rebukes the FDA's request to halt shipments of its gene therapy drug. Why one Wall Street analyst says the stock could head to zero. Fast Money Disclaimer  

Another morning of record highs on the S&P and NASDAQ ahead of a make-or-break week for stocks: Sara Eisen and Carl Quintanilla started the hour with a look at the major earnings coming this week (Alphabet, Tesla, Intel, and more), and what we've heard from key companies so far. Barclays Head of U.S. Equity Strategy arguing this will be the first quarter to show the impact of tariffs – but the headwinds just haven't shown up yet. Plus: a deep dive on new numbers out of Domino's with an analyst who calls the stock a buy, as their CFO says they've seen no geopolitical impact to their business.  Also in focus: hear from the CEO of the credit bureau FICO as his company comes under fire for being a “monopoly” – why he says it's just the most efficient way for the market to operate, how he's using AI in the business, and more… and the latest on the biggest movers of the day, from Sarepta to Apple to LVMH.Squawk on the Street Disclaimer

Chevron CEO Mike Wirth joined Carl Quintanilla and Sara Eisen at Post 9 in a "First on CNBC" interview. They discussed the oil giant completing its $55 billion acquisition of Hess. Shares of Netflix pull back from all-time highs despite better-than-expected quarterly results. One analyst offers his take on where the stock and the streaming wars go from here. New record intraday highs for the S&P 500 and Nasdaq -- a chief investment strategist joins the discussion about what's next for the rally. Also in focus: Reaction to earnings from the likes of American Express, Sarepta tumbles, President Trump vs. Fed Chair Powell, the House of Representatives passes landmark crypto legislation, CBS cancels Stephen Colbert's "Late Show."   Squawk on the Street Disclaimer